Drug Profile
Paclitaxel coated balloon - Lutonix/C.R. Bard
Alternative Names: Lutonix; Lutonix 35 drug coated balloon PTA catheter; Lutonix paclitaxel DCB; Lutonix paclitaxel-coated balloon - Lutonix/CR Bard; Lutonix paclitaxel-coated PTA dilatation catheter; Lutonix® Drug Coated PTA Dilatation Catheter; MD02-LDCB; Paclitaxel-coated percutaneous transluminal angioplasty balloon - Lutonix/CR BardLatest Information Update: 15 Jan 2022
Price :
$50
*
At a glance
- Originator Lutonix
- Developer CR Bard; Lutonix
- Class Antineoplastics; Diterpenes; Paclitaxels; Skin disorder therapies; Small molecules; Taxanes; Vascular disorder therapies
- Mechanism of Action Mitosis inhibitors; Platelet-derived growth factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Peripheral arterial disorders
Most Recent Events
- 01 Mar 2019 CR Bard completes a phase III trial for Peripheral arterial disorders in USA (NCT02063672)
- 25 Jun 2015 Updated efficacy results from the Levant 2 phase II trial in Peripheral arterial disorders released by C.R. Bard
- 23 Oct 2014 Launched for Peripheral arterial disorders in USA (Intra-arterial)